Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. T-LITEs incorporate a small molecule-controlled switch into a conventional bispecific t-cell engaging antibody which enables precise on/off control over the timing and magnitude of redirected T-cell cytotoxic activity. Soteria was founded in 2018 with technology licensed from UC San Francisco and is based in San Francisco, California.
Proceeds to fund early pipeline of novel switchable bispecific T-cell engagers to treat solid tumor cancers
Company's proprietary T-LITE platform based on small molecule-dependent activation of T-cell engagers, enabling potentially safer and more efficacious tumor targeted therapy
Seasoned leadership to steer company's growth and pipeline development
2020/11/12Soteria Biotherapeutics, Inc. today announced the formation of a scientific advisory board to help guide the company's early stage research and development.
